ARCT News and Press, Arcturus Therapeutics Ltd. From 04/11/23

2023-04-11 13:03:15 ET Summary Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline deve...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-28 19:02:04 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Conference Call March 28, 2023 04:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - CFO Padmanabh Chivukula - Chief Scienti...

2023-03-28 18:08:06 ET A combination of quarterly results beating on the top and bottom lines and an extension of its cash runway into 2026 has propelled Arcturus Therapeutics ( NASDAQ: ARCT ) ~21% higher in after-hours trading. The runway extension is due to the ...

2023-03-28 16:02:10 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q4 EPS of $4.33 may not be comparable to consensus of $1.23. Revenue of $160.29M (+2663.6% Y/Y) beats by $79.77M . For further details see: Arcturus Therapeutics EPS of $4.33, revenu...

$200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-8...

2023-03-27 17:35:56 ET Arcturus Therapeutics ( NASDAQ: ARCT ) is scheduled to announce Q4 earnings results on Tuesday, March 28th, after market close. The consensus EPS Estimate is $1.23 and the consensus Revenue Estimate is $80.52M (+1288.3% Y/Y). Over the last 3 mont...

2023-03-27 17:35:09 ET Major earnings expected after the bell on Tuesday include: Micron Technology ( MU ) Lululemon Athletica ( LULU ) Ideanomics ( IDEX ) Emeren Group ( SOL ) nCino ( NCNO ) For further details see: Notable earnings after...

Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day, April 3, 2023 Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...